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Aim To investigate the association of adiponectin and re-
sistin levels in patients undergoing hematopoietic stem 
cell transplantation (HSCT) with the clinical outcome, in-
cluding the occurrence of acute and chronic graft-vs-host 
disease (GVHD), non-relapse mortality, and overall survival.
Methods We prospectively collected serum samples 
from 40 patients undergoing either autologous (n = 12; 
10 male) or allogeneic (n = 28; 11 male) HSCT for up to 12 
months post HSCT and determined adiponectin and re-
sistin serum concentrations using enzyme-linked immu-
nosorbent assay.
Results There were no significant differences in adiponec-
tin levels (18.5 vs 9.3 µg/mL, P = 0.071) and adiponectin/
BMI ratio (0.82 vs 0.39, P = 0.068) between patients with 
acute GVHD grades 2-4 and autologous controls. Howev-
er, resistin values were significantly lower in patients with 
acute GVHD grades 2-4 than in autologous controls (4.6 
vs 7.3 ng/mL, P = 0.030). Adiponectin levels were higher 
in patients with chronic GVHD (n = 17) than in autologous 
controls (13.5 vs 7.6 µg/mL, P = 0.051), but the difference 
was not significant. Adiponectin/BMI ratio was significantly 
higher in patients with chronic GVHD than in autologous 
controls (0.59 vs 0.25, P = 0.006). Patients dying from relapse 
also had significantly lower adiponectin levels (8.2 µg/mL) 
and adiponectin/BMI ratio (0.3) on admission than surviv-
ing allogeneic (15.8 µg/mL, P = 0.030 and 0.7, P = 0.004) and 
surviving autologous patients (19.2 µg/mL, P = 0.031 and 
0.7, P = 0.021).
Conclusion Adiponectin and resistin levels were altered in 
patients with acute and chronic GVHD compared to autolo-
gous controls and were associated with overall survival and 
relapse mortality in patients undergoing allogeneic HSCT.
Received: January 27, 2016
Accepted: June 1, 2016
Correspondence to:  
Oliver Robak 
Department of Internal Medicine I, 
Intensive Care Unit  
Medical University of Vienna  
Waehringer Guertel 18-20  
A-1090 Vienna, Austria 
oliver.robak@meduniwien.ac.at
Oliver Robak1, Zoya 
Kuzmina1, Andreas 
Winkler1, Peter Kalhs1, 
Werner Rabitsch1, 
Hildegard Greinix1,2
1Department of Medicine I, Medical 
University of Vienna, Vienna, Austria
2Division of Hematology, Medical 
University of Graz, Graz, Austria
Adiponectin and resistin in 
acute and chronic graft-vs-host 
disease patients undergoing 




Croat Med J. 2016;57:255-65 
doi: 10.3325/cmj.2016.57.255
GRAFT-VS-HOST DISEASE 256 Croat Med J. 2016;57:255-65
www.cmj.hr
Allogeneic hematopoietic stem cell transplantation 
(HSCT) offers potential cure to an increasing number of 
patients with hematological diseases (1,2). However, it is 
still associated with substantial morbidity related in part 
to graft-vs-host disease (GVHD). GVHD occurs in around 
50% of recipients and presents a major complication 
(3-5). Severe GVHD is associated with reduced survival (6) 
and impaired quality of life (7). Chronic GVHD (cGVHD) is 
one of the main causes of non-relapse mortality (NRM) 
and prolonged immunodeficiency (3,4). Clinical signs of 
cGVHD can resemble those of autoimmune disorders 
such as systemic lupus erythematosus, Sjogren’s syn-
drome, scleroderma, autoimmune thyroiditis, and rheu-
matoid arthritis (8-10). In 2005, the National Institutes of 
Health (NIH) defined the criteria for diagnosis and sever-
ity scoring of cGVHD (11,12).
Acute GVHD (aGVHD) is an inflammatory disorder that oc-
curs when transplanted donor T-lymphocytes react to host 
cells and tissues that are recognized as foreign (13). Pro-in-
flammatory cytokines like interleukin-1 (IL1), interleukin-6 
(IL6), and tumor necrosis-factor (TNF)-alpha are up-regu-
lated and contribute to the high morbidity and mortality. 
Importantly, macrophages exhibit potent regulatory func-
tions in vivo with the help of T-cells (14).
Adipokines are cytokines secreted predominately by the 
adipose tissue. They exert a variety of distinct metabolic, 
endocrine, and immune functions, both locally and sys-
temically. Adiponectin is an adipocyte-derived secretory 
protein, which is an important regulator of inflammatory 
responses (15,16). In many inflammatory states, adiponec-
tin levels are inversely correlated with pro-inflammatory 
markers (17-19). Overall, adiponectin exerts predominant-
ly anti-inflammatory effects and suppresses the prolifera-
tion of myelomonocytic progenitor cells (20,21). Further-
more, it inhibits the classical pro-inflammatory function of 
macrophages, promoting an M2 macrophage phenotype 
(22), and diminishing phagocytosis and cytokine produc-
tion upon lipopolysaccharide-stimulation by interfering 
with nuclear factor kappa-B activation (23). This is also 
an important mechanism during HSCT, as recipient mac-
rophages contribute to GVHD by antigen-presentation 
and secretion of cytokines, causing the activation and 
proliferation of CD8+ T cells (24,25). Moreover, adiponectin 
reduces T-lymphocyte recruitment via reduction of inter-
feron-beta production (26). In a model of murine cardiac 
transplantation, adiponectin attenuated allograft rejec-
tion in major histocompatibility complex class II mis-
matched transplants (27).
Another adipokine, resistin, forms an important link be-
tween obesity, insulin resistance, and diabetes (28,29). In 
humans, increased levels of resistin have been found in 
mononuclear leukocytes and macrophages (30). Resistin 
has further been associated with inflammation in system-
ic autoimmune diseases (31) and might counteract adi-
ponectin action with regards to macrophage function by 
promoting a pro-inflammatory state (32,33).
An association between serum high-molecular-weight 
(HMW) adiponectin levels and cGVHD severity in alloge-
neic HSCT recipients was first suggested in a retrospective 
analysis by Nakasone et al (34). However, they investigated 
HMW-adiponectin only and did not take into account that 
adiponectin levels inversely correlated with the body mass 
index (BMI) (35,36). We performed a prospective study to 
investigate the association of total adiponectin and classi-
cal inflammatory markers and the transplant outcome in-
cluding the occurrence of aGVHD and cGVHD, as well as 
relapse and survival. Besides adiponectin levels, we calcu-
lated the ratio of the absolute adiponectin plasma levels 
and BMI in order to compensate for the fact that adiponec-
tin levels are closely correlated with adipose tissue mass 
and body mass index (37,38). Whereas Nakasone et al (34) 
compared autologous transplant recipients to healthy con-
trols (34), we compared them to allogeneic ones, in order 
to have patient groups with comparable toxicity profiles 
related to the administration of conditioning therapies.
PAtients And metHOds
Patients and study design
Between November 2008 and December 2010, we pro-
spectively collected serum samples from patients undergo-
ing either autologous (n = 12; 10 male) or allogeneic (n = 28; 
11 male) HSCT (Table 1). Blood samples were obtained 
at the following time points: on admission (7 days before 
HSCT; T-1), on the day of HSCT (T0), during aplasia (defined 
by absolute neutrophil count <0.5 G/L; T+1), on the day of 
engraftment (defined by absolute neutrophil count >0.5 
G/L; T+2), 1 month after HSCT (T+3), 3 to 6 months after 
HSCT (T+4), and 6 to 12 months after HSCT (T+5).
41 consecutive patients were included into the study. 1 pa-
tient died two days after enrolment and was excluded from 
the analysis, leaving 40 patients for the analysis. Patients 
were enrolled prior to the start of myeloablative (n = 26) 
or reduced-intensity conditioning (RIC, n = 14) for HSCT. 
Autologous HSCT patients (n = 12) served as controls. The 
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diagnosis and the severity of aGVHD and cGVHD were de-
termined based on the modified Glucksberg and NIH clas-
sification (11,39,40). All patients received anti-infective 
prophylaxis as previously described (41). This study was 
approved by the Institutional Review Board of the Medi-
cal University of Vienna. All patients gave written informed 
consent in accordance with the Declaration of Helsinki.
enzyme-linked immunosorbent assay
Serum adiponectin and resistin concentrations were mea-
sured using enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer’s instructions (Resistin and 
Adiponectin Human ELISA, BioVendor R&D, Brno, Czech 
Republic). Since adiponectin levels closely correlate with 
adipose tissue mass and BMI (37,38), values were addition-
ally calculated as ratio adiponectin/BMI (42). The reference 
range of adiponectin plasma levels is between 2 and 15 
µg/mL (43,44) and that of resistin plasma levels is between 
10 and 30 ng/mL (45). Serum amyloid-A (SAA), hapto-
globin (HPT), and fibronectin (FNC) were measured as clas-
sical markers of inflammation by nephelometry (Behring 
Nephelometer, Siemens Healthcare Diagnostics GmbH, 
Munich, Germany).
tAble 1. Patients’ characteristics
All n (%) Allogeneic n (%) Autologous n (%)
number of patients 40 (100) 28 (70) 12 (30)
median age in years (range) 46 (34-56) 44 (34-56) 48 (42-49)
sex
male 21 (53) 11 (39) 10 (83)
female 19 (47) 17 (61)  2 (17)
bmi on admission 22.9 25.8
bmi overall mean (range) 25 (17.6-33) 24.6 (17.6-33)† 25.8 (19-31.2)†
diagnosis
acute myeloid leukemia 21 (53) 21 (75)  0 (0)
chronic myeloid leukemia  1 (3)  1 (4)  0 (0)
lymphoma  9 (23)  5 (18)  4 (33)
myeloma  6 (15)  0 (0)  6 (50)
other‡  3 (8)  1 (4)  2 (17)
disease status at transplantation
standard risk§ 21 (53) 15 (54)  6 (50)
high risk§ 19 (48) 13 (46)  6 (50)
Conditioning
myeloablative 26 (65) 14 (50) 12 (100)
Reduced-intensity conditioning 14 (35) 14 (50)  0 (0)
stem cell donors
related 11 (39) 11 (39)  N/A
unrelated 17 (61) 17 (61)  N/A
HLA-identical 21 (75) 21 (75)  N/A
HLA-mismatched  7 (25)  7 (25)  N/A
stem cell source
bone marrow  1 (3)  1 (4)  0 (0)
peripheral blood stem cells 39 (98) 27 (96) 12 (100)
Post-transplant immunosuppressive prophylaxis
cyclosporine only  4 (10)  4 (14)  N/A
cyclosporine-methotrexat 14 (35) 14 (50)  N/A
cyclosporine-mycophenolate mofetil 10 (25) 10 (36)  N/A
median follow-up, months (range) 26 (0.1-46) 24 (0.1-46) 30.3 (4.3-46)
*n – number of patients; bmi – body mass index; HlA – human leukocyte antigen.
†difference between groups is statistically significant.
‡Other diagnoses included myelodysplastic syndrome and chronic lymphocytic leukemia. §standard risk was defined as acute leukemia in the first 
or second complete remission or chronic myeloid leukemia in the first chronic phase. High-risk disease included myelodysplastic syndrome, acute 
and chronic leukemia beyond second complete remission or in relapse, as well as chronic myeloid leukemia beyond the first chronic phase.
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statistical analysis
NRM was defined as any death not related to the underly-
ing malignancy. Relapse was defined as recurrence of ma-
lignancy after achievement of complete remission, with 
NRM as a competing risk. Cumulative incidences of acute 
and chronic GVHD were estimated considering relapse/
progression and death as a competing event. OS was cal-
culated from the day 0 of HSCT to the day of death from 
any cause or last follow-up.
Normality was tested using the Kolmogorov-Smirnov 
test. Serum levels in patient groups were compared using 
unpaired t test in case of variables with normal distribu-
tion, otherwise the Mann-Whitney U test was used. Fisher 
exact test was used to test the significance of the asso-
ciation between two variables. Multiple linear regression 
was used to determine the relationship between two or 
more explanatory variables and a response variable. Dif-
ferences were considered statistically significant at a two-
sided P value <0.05. P-values were corrected for multiple 
testing. The data are presented as mean and standard de-
viation or median and interquartile range. Statistical anal-




The study included 40 patients. Apart from sex and disease, 
there were no significant differences in patient character-
istics between the autologous and the allogeneic HSCT 
patients (Table 1). Women had slightly higher adiponectin 
levels and adiponectin/BMI ratios, but the difference was 
not significant (P = 0.053, t test) (34-36).
Adiponectin and resistin during HsCt
Patients who received myeloablative conditioning (n = 14) 
had significantly lower adiponectin levels at T0 (11 vs 25.3 
µg/mL, P = 0.028, t test) and significantly higher resistin lev-
els at T+2 (2.9 vs 3.8 ng/mL, P = 0.029, t test) than patients 
receiving RIC (n = 14).
No other patient characteristic or clinical parameter (age, 
sex, BMI, donor source, HLA identity, stem cell source, and 
GVHD prophylaxis) had a significant impact on adiponec-
tin and resistin levels (multiple linear regression).
Acute GVHd
Cumulative incidence of aGVHD was 64% (n = 18) at a 
mean of 21.5 (16.5-32) days after HSCT, including 67% 
of patients (n = 12) with grades 2-4 (Table 2). Mean adi-
ponectin levels in patients with established aGVHD grades 
2-4 were 18.5 ± 9.7 µg/mL compared to 9.3 ± 4.8 µg/mL 
(P = 0.071, t test) in autologous HSCT controls (Figure 1A, 
measured at disease maximum); mean adiponectin/BMI 
ratio in patients with established aGVHD grades 2-4 was 
0.82 ± 0.3 compared to 0.39 ± 0.30 (P = 0.068, t test) in au-
tologous controls (Figure 1B, measured at disease maxi-
mum). Mean resistin levels in patients with established 
aGVHD were 4.6 ± 3.3 ng/mL compared to 7.3 ± 2.1 ng/mL 
in autologous controls (P = 0.030, t test, Figure 1A, mea-
sured at disease maximum). Resolution of aGVHD without 
later development of cGVHD (n = 7) was associated with 
a decrease in adiponectin levels to a mean of 13.2 ± 10.4 
µg/mL (P = 0.037, Mann-Whitney-U test) and an increase 
in resistin levels to 13.8 ± 2.5 ng/mL (P = 0.033, Mann-Whit-
ney-U test).
tAble 2. Characteristics of acute graft vs host disease (aGVHd) 
and chronic GVHd (cGVHd)*†
aGVHd n (%) cGVHd n (%)
total 18 (64)  17 (61)
sex patient (female) 10 (56)  11 (65)
sex donor (female) 8 (44)   6 (35)
CmV patient positive 11 (61)   8 (47)
CmV donor positive 12 (67)  10 (59)
Organ involvement
skin 14 (78)  11 (65)
eyes  11 (65)
oral mucosa   8 (47)
liver 10 (56)  10 (59)
lungs   4 (24)
gastrointestinal system 10 (56)   2 (12)
joints   1 (6)
severity score (disease maximum) Glucksberg NIH
1  6 (33)  10 (59)
2  7 (39)   4 (24)
3  4 (22)   3 (18)
4  1 (6)   0 (0)
Onset type of cGVHd
de novo   6 (35)
quiescent   6 (35)
progressive   5 (29)
median time to first onset of 
GVHd in days, (range)
27 (10-80) 123 (75-222)
*CmV – cytomegalovirus.
†data displayed as cumulative incidences.
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Patients with subsequent aGVHD grades 2-4 (n = 18) had 
significantly higher adiponectin levels (23.4 vs 9.6 µg/mL, 
P = 0.041, t test) and adiponectin/BMI ratios (1.0 vs 0.4, 
P = 0.008, t test) during aplasia than autologous controls 
(Figure 2). They also had significantly reduced resistin until 
day 32 (the day of the latest aGVHD diagnosis) than con-
trols at T+1 (5.3 vs 13.3 ng/mL, P = 0.001, and 5.1 vs 7.3 ng/
mL, P = 0.033, t test).
Besides a significant reduction in SAA (30.7 vs 145 µg/mL, 
P = 0.04) at engraftment and 1 month after HSCT, no dif-
ferences in other classical inflammation markers were ob-
served between patients with aGVHD grades 2-4 and au-
tologous controls.
Except for donor source (related vs unrelated donor, 39% 
vs 61%, P = 0.050, t test) and BMI, no other patient charac-
teristic or clinical parameter (age, sex, HLA identity, stem 
cell source, conditioning regime, and GVHD prophylaxis) 
had an impact on the incidence of acute GVHD (multiple 
linear regression).
Chronic GVHd
Cumulative incidence of cGVHD was 61% (n = 17) at a 
mean of 123 (range, 75-222) days after HSCT, including 
41% (n = 7) patients with grades 2-3 (Table 2). Adiponectin 
levels were elevated in patients with established moderate 
to severe cGVHD (n = 17) compared to autologous controls 
(13.5 vs 7.6 µg/mL, P = 0.051, t test, Figure 3A, measured 
at disease maximum) but the difference was not signifi-
cant. Adiponectin/BMI ratios were significantly higher in 
patients with established moderate/severe cGVHD than in 
autologous controls (0.59 vs 0.25, P = 0.006,, t test, Figure 
3B, measured at disease maximum). No significant differ-
ences in resistin levels were observed compared to autolo-
gous controls or allogeneic patients with no cGVHD.
At the time point prior to the onset of cGVHD, future 
cGVHD patients had a significantly higher adiponectin/BMI 
ratio (0.9 vs 0.2, P = 0.032, t test) than autologous controls. 
Also, they had significantly higher adiponectin levels (16.9 
vs 9.6 µg/mL, P = 0.042) and adiponectin/BMI ratios during 
aplasia (T+1) (0.8 vs 0.4, P = 0.038, t test).
FiGuRe 1. Adiponectin (AdiPOQ) and resistin (Res) levels (A) and AdiPOQ/body mass index (bmi) ratio (B) in patients with estab-
lished acute acute graft vs host disease (aGVHd) compared to autologous controls; measured at disease maximum.
FiGuRe 2. Adiponectin (AdiPOQ) (A) and AdiPOQ/body mass 
index (bmi) ratio (B) in patients subsequently developing 
acute graft vs host disease (aGVHd) compared to autologous 
controls during aplasia.
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Patients with cGVHD also had significantly higher FNC lev-
els on admission (33.6 vs 7.8 µg/mL, P < 0.001, t test) and 
higher SAA levels 1 month after HSCT (13.8 vs 4.9, P = 0.033, 
t test) than autologous controls. When compared to non-
cGVHD patients (n = 11), patients with cGVHD only had sig-
nificantly reduced SAA at T0 and T+4 (9 vs 262, P = 0.034 
and 5 vs 72, P = 0.010, t test).
Patient outcome
Overall, 13 patients (32%) died within a mean of 8 months 
after HSCT. Prior to HSCT (T-1), only HPT levels were sig-
nificantly higher in all patients subsequently dying than 
in all survivors of HSCT (135 vs 82 µg/mL, P = 0.013, t test). 
From T+2 through T+5, resistin, but not adiponectin or 
adiponectin/BMI ratio, was significantly higher in non-sur-
viving allogeneic patients than in surviving allogeneic pa-
tients (Figure 4). Patient characteristics and clinical param-
eters that had an impact on overall survival in multivariate 
analyses were lower age at T0 (P = 0.052, multiple linear re-
gression), but not sex, conditioning, HLA identity, stem cell 
source, or GVHD prophylaxis. Importantly, we did not ob-
serve differences in mortality, relapse, aGVHD, and cGVHD 
with regard to sex.
9 patients (22.5%) died within a mean of 4.7 months after 
HSCT due to relapse of their primary diseases. 4 patients 
(10%) died within a mean 14.5 months after HSCT due to 
causes that were not related to their primary disease (non-
relapse mortality, NRM; causes of death: sarcoma, infection, 
cGVHD, aGVHD).
Patients dying from relapse had significantly lower adi-
ponectin levels (8.2 vs 30.4 µg/mL, P = 0.007) and adiponec-
tin/BMI ratios (0.3 vs 1.1, P = 0.004) prior to HSCT (T-1) than 
patients experiencing NRM. Patients dying from relapse 
also had significantly lower adiponectin levels (8.2 µg/mL) 
and adiponectin/BMI ratio (0.3) at T-1 than surviving allo-
geneic (15.8 µg/mL, P = 0.030 and 0.7, P = 0.004, t test) and 
surviving autologous patients (19.2 µg/mL, P = 0.031 and 
0.7, P = 0.021, t test). Throughout the whole study period, 
patients dying from relapse had higher adiponectin levels 
and adiponectin/BMI ratio than surviving allogeneic pa-
tients and all surviving patients (Figure 5). Allogeneic NRM 
patients (n = 4) did not show significantly different levels of 
FiGuRe 3. Adiponectin (AdiPOQ) and resistin (Res) levels (A), and AdiPOQ/body mass index (bmi) ratio (B) in chronic graft vs host 
disease (cGVHd) patients compared to autologous controls; measured at disease maximum.
FiGuRe 4. Resistin (Res) levels in relapsing non-survivors com-
pared to surviving allogeneic patients.
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adiponectin, resistin, or adiponectin/BMI ratio from surviv-
ing allogeneic patients. No impact of patient clinical char-
acteristics on NRM or relapse was observed (multiple linear 
regression).
disCussiOn
Our study was the first to show elevated adiponectin lev-
els and adiponectin/BMI ratio in aGVHD and cGVHD and 
lower resistin levels in aGVHD. Also, patients dying from re-
lapse had higher adiponectin levels and adiponectin/BMI 
ratio than surviving allogeneic patients. Adiponectin lev-
els and adiponectin/BMI ratio were significantly higher in 
established moderate/severe cGVHD. These results are in 
accordance with the previous work by Nakasone (34). Fur-
thermore, we reported a predictive value of adiponectin 
and resistin during aplasia (T+1) for subsequent develop-
ment of aGVHD and cGVHD, suggesting that a change in 
adipokine levels precedes GVHD. This has not been shown 
before and might reflect pathophysiologic changes that 
take place at a very early stage before the appearance of 
clinical signs of GVHD. We interpret these results as a stron-
ger, probably compensatory anti-inflammatory response in 
patients with a subsequent development of aGVHD direct-
ly after HSCT (at T+1), probably due to more tissue damage 
following conditioning and a consecutive pro-inflamma-
tory up-regulation of resistin and SAA (at T+2 and T+3) at 
the initiation of aGVHD. Considering the anti-inflammatory 
properties of adiponectin and the pro-inflammatory prop-
erties of resistin, this phenomenon might represent two 
phases of the immunologic state activation of the white 
adipose tissue during GVHD.
An important finding of our study was that adiponectin 
levels and adiponectin/BMI ratios prior to HSCT (T-1) were 
significantly lower in patients subsequently dying from a 
relapse of their underlying disease. While this finding might 
not necessarily be causally connected to HSCT, it may still 
indicate that adipokines are involved in a broader regula-
tion of the immune response during critical illnesses, with 
higher levels probably having a protective role. However, 
since we investigated HSCT patients only, this statement 
remains speculative. Resolution of aGVHD was accompa-
nied by a significant reduction of adiponectin and resistin 
levels, as reported earlier (34).
The factors associated with improved overall survival were 
younger age and a normal BMI (18.5-25). While older age 
is unarguably associated with a worse outcome (1,3-5), 
conflicting data have been reported on BMI (46-48). Since 
most of our patients had normal body weight or were 
overweight (BMI 25-30) at admission, our findings cannot 
be applied to obese or underweight patients. Therefore, 
we could not confirm previously reported higher survival 
rates in patients with a BMI>30 (49).
We observed lower adiponectin levels and adiponectin/
BMI ratios in patients who received myeloablative condi-
tioning regimen compared to RIC. At present, there is no 
evidence if and how the conditioning regimen impacts 
adipocytes, the main source of adiponectin in humans. We 
can only speculate that myeloablative conditioning de-
creases adiponectin production by adipocytes or the adi-
pocyte population itself. However, this observation might 
not indicate a causal relationship.
Annaloro et al (50) reported lower adiponectin levels in 
long-term allogeneic HSCT survivors with metabolic syn-
drome and higher BMI. Demographic characteristics of 
these patients were comparable to those of our par-
FiGuRe 5. Adiponectin (AdiPOQ) (A) and AdiPOQ/body mass index (bmi) ratio (B) in surviving autologous, surviving allogenous, non-
relapsing non-survivors (nRm), and relapsing non-survivors (Rm) in the course of hematopoietic stem cell transplantation (HsCt).
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ticipants, as were adiponectin levels. In this study, GVHD 
was not a predictor of metabolic syndrome in the subset of 
allogeneic HSCT recipients. Since adiponectin levels were 
inversely correlated with BMI but also were higher in GVHD 
patients with similar BMI, this finding might indicate that 
adiponectin is indeed involved in the pathophysiology of 
GVHD. However, Annaloro et al did not report any correla-
tion with mortality or GVHD.
Adiponectin acts both pro- and anti-inflammatory, though 
most authors report only its anti-inflammatory properties. 
This makes the interpretation of the results particularly dif-
ficult: is adiponectin an additional factor causing GVHD or 
is it a key regulator inhibiting proinflammatory responses? 
Since in our study adiponectin/BMI ratios were higher in 
the non-relapsing and surviving patients, we propose that 
adiponectin has an anti-inflammatory effect during alloge-
neic HSCT. This assumption is supported by Katsiougiannis 
et al (51), who demonstrated that adiponectin protects sal-
ivary gland epithelial cells from apoptosis in Sjogren’s syn-
drome. Nakasone et al (34), on the other hand, proposed 
pro- and anti-inflammatory action in GVHD.
Proinflammatory action of adiponectin has been described 
mostly in vitro (52-54). Since recombinant adiponectin is 
very often contaminated by LPS (55) and its proinflamma-
tory properties have not been described in vivo, we think 
that a relevant proinflammatory action of adiponectin in 
GVHD can currently be neglected.
The design of this study does not allow further in-depth 
investigation of the underlying mechanisms, so conclu-
sions about them have to be drawn very carefully. The 
small sample size also poses a significant limitation, al-
though the prospective design might counterbalance this. 
Furthermore, we speculated that adiponectin and resistin 
actions were not specific for GVHD, however we failed to 
provide evidence for this assumption. We cannot answer 
the very relevant question posed by Nakasone et al (34) 
whether high adiponectin levels in cGVHD are a primary 
or a secondary event. Another limitation is that we did not 
differentiate between different forms of adiponectin, since 
recent reports have shown that distinct isoforms might in-
duce different effects in vivo and in vitro (56-58). We con-
firmed previous findings that adiponectin levels and adi-
ponectin/BMI ratios were higher in women (37,38). Since 
in our study the autologous HSCT group consisted mainly 
of male patients, adiponectin levels in this group might 
be lower than in a group with equal sex distribution. 
This has to be taken into account in further stud-
ies. Although we did provide data on survival, the primary 
aim of the study was not to detect differences in mortal-
ity. However, some results indicate a possible involvement 
of adipokines in the pathomechanism of relapse, which 
might be a useful basis for further research.
Our data suggest a distinct expression of adiponectin and 
resistin during the course of HSCT. In this regard, further re-
search is needed to clarify our observations. The next logi-
cal step would be to correlate the anti-inflammatory action 
in GVHD with specific adiponectin isoforms in a prospec-
tive study. In conclusion, adiponectin and resistin were al-
tered during the occurrence of acute and chronic GVHD 
and were associated with overall survival and relapse mor-
tality in patients undergoing allogeneic HSCT compared 
to autologous controls. Both cytokines could have a role in 
the pathophysiology of GVHD and should be evaluated in 
further studies.
Funding Institutional funding only (scientific budget of the Medical Uni-
versity of Vienna).
ethical approval Received from the Institutional Review Board of the Medi-
cal University of Vienna.
declaration of authorship OR and WR designed the study, analyzed and in-
terpreted the data.. ZK analyzed and interpreted the data, and co-authored 
the manuscript. AW performed the clinical research, collected data, and 
performed the ELISAs. HG, and PK interpreted the data and provided sci-
entific input.
Competing interests All authors have completed the Unified Competing 
Interest form at www.icmje.org/coi_disclosure.pdf (available on request 
from the corresponding author) and declare: no support from any organi-
zation for the submitted work; no financial relationships with any organiza-
tions that might have an interest in the submitted work in the previous 3 
years; no other relationships or activities that could appear to have influ-
enced the submitted work.
References
1 Appelbaum FR. Hematopoietic-cell transplantation at 50. n 
engl J med. 2007;357:1472-5. medline:17928594 doi:10.1056/
neJmp078166
2 Passweg JR, baldomero H, Gratwohl A, bregni m, Cesaro s, dreger 
P, et al. the ebmt activity survey: 1990-2010. bone marrow 
transplant. 2012;47:906-23. medline:22543746 doi:10.1038/
bmt.2012.66
3 lee sJ, Vogelsang G, Gilman A, Weisdorf dJ, Pavletic s, Antin 
JH, et al. A survey of diagnosis, management, and grading 
of chronic GVHd. biol blood marrow transplant. 2002;8:32-9. 
medline:11846354 doi:10.1053/bbmt.2002.v8.pm11846354
4 socie G, stone JV, Wingard JR, Weisdorf d, Henslee-downey 
PJ, bredeson C, et al. long-term survival and late deaths after 
allogeneic bone marrow transplantation. late effects Working 
Committee of the international bone marrow transplant Registry. 
n engl J med. 1999;341:14-21. medline:10387937 doi:10.1056/
neJm199907013410103
263Robak et al: Adiponectin and resistin in allogeneic HSCT
www.cmj.hr
5 Jagasia m, Arora m, Flowers me, Chao nJ, mcCarthy Pl, Cutler Cs, 
et al. Risk factors for acute GVHd and survival after hematopoietic 
cell transplantation. blood. 2012;119:296-307. medline:22010102 
doi:10.1182/blood-2011-06-364265
6 Pasquini mC. impact of graft-versus-host disease on survival. best 
Pract Res Clin Haematol. 2008;21:193-204. medline:18503986 
doi:10.1016/j.beha.2008.02.011
7 Pidala J, Anasetti C, Jim H. Quality of life after allogeneic 
hematopoietic cell transplantation. blood. 2009;114:7-19. 
medline:19336756 doi:10.1182/blood-2008-10-182592
8 Rouquette-Gally Am, boyeldieu d, Gluckman e, Abuaf n, 
Combrisson A. Autoimmunity in 28 patients after allogeneic bone 
marrow transplantation: comparison with sjogren syndrome 
and scleroderma. br J Haematol. 1987;66:45-7. medline:3297128 
doi:10.1111/j.1365-2141.1987.tb06888.x
9 Cwynarski K, Goulding R, Pocock C, dazzi F, Craddock C, Kaeda 
J, et al. immune haemolytic anaemia following t cell-depleted 
allogeneic bone marrow transplantation for chronic myeloid 
leukaemia: association with leukaemic relapse and treatment 
with donor lymphocyte infusions. bone marrow transplant. 
2001;28:581-6. medline:11607771 doi:10.1038/sj.bmt.1703206
10 Rouquette-Gally Am, boyeldieu d, Prost AC, Gluckman e. 
Autoimmunity after allogeneic bone marrow transplantation. 
A study of 53 long-term-surviving patients. transplantation. 
1988;46:238-40. medline:3043780 doi:10.1097/00007890-
198808000-00010
11 Filipovich AH, Weisdorf d, Pavletic s, socie G, Wingard JR, lee sJ, 
et al. national institutes of Health consensus development project 
on criteria for clinical trials in chronic graft-versus-host disease: i. 
diagnosis and staging working group report. biol blood marrow 
transplant. 2005;11:945-56. medline:16338616 doi:10.1016/j.
bbmt.2005.09.004
12 Jagasia mH, Greinix Ht, Arora m, Williams Km, Wolff d, Cowen eW, 
et al. national institutes of Health Consensus development Project 
on Criteria for Clinical trials in Chronic Graft-versus-Host disease: i. 
the 2014 diagnosis and staging Working Group report. biol blood 
marrow transplant. 2015;21(3):389-401 e381. medline:25529383 
doi:10.1016/j.bbmt.2014.12.001 
13 Goker H, Haznedaroglu iC, Chao nJ. Acute graft-vs-host disease: 
pathobiology and management. exp Hematol. 2001;29:259-77. 
medline:11274753 doi:10.1016/s0301-472X(00)00677-9
14 liu W, Xiao X, demirci G, madsen J, li XC. innate nK cells and 
macrophages recognize and reject allogeneic nonself in vivo 
via different mechanisms. J immunol. 2012;188:2703-11. 
medline:22327074 doi:10.4049/jimmunol.1102997
15 Fantuzzi G. Adiponectin and inflammation: consensus 
and controversy. J Allergy Clin immunol. 2008;121:326-30. 
medline:18061654 doi:10.1016/j.jaci.2007.10.018
16 Zacharioudaki V, Androulidaki A, Arranz A, Vrentzos G, 
margioris An, tsatsanis C. Adiponectin promotes endotoxin 
tolerance in macrophages by inducing iRAK-m expression. J 
immunol. 2009;182:6444-51. medline:19414798 doi:10.4049/
jimmunol.0803694
17 behnes m, brueckmann m, lang s, Putensen C, saur J, borggrefe 
m, et al. Alterations of adiponectin in the course of inflammation 
and severe sepsis. shock. 2012;38:243-8. medline:22744305 
doi:10.1097/sHK.0b013e318261e0dc
18 trellakis s, Rydleuskaya A, Fischer C, Canbay A, tagay s, 
scherag A, et al. low adiponectin, high levels of apoptosis 
and increased peripheral blood neutrophil activity in healthy 
obese subjects. Obes Facts. 2012;5:305-18. medline:22722748 
doi:10.1159/000339452
19 Robinson K, Prins J, Venkatesh b. Clinical review: adiponectin 
biology and its role in inflammation and critical illness. Crit Care. 
2011;15:221. medline:21586104 doi:10.1186/cc10021
20 Yokota t, Oritani K, takahashi i, ishikawa J, matsuyama A, Ouchi n, 
et al. Adiponectin, a new member of the family of soluble defense 
collagens, negatively regulates the growth of myelomonocytic 
progenitors and the functions of macrophages. blood. 
2000;96:1723-32. medline:10961870
21 Wang Y, lam Ks, Xu JY, lu G, Xu lY, Cooper GJ, et al. Adiponectin 
inhibits cell proliferation by interacting with several growth 
factors in an oligomerization-dependent manner. J biol Chem. 
2005;280:18341-7. medline:15734737 doi:10.1074/jbc.m501149200
22 mandal P, Pratt bt, barnes m, mcmullen mR, nagy le. molecular 
mechanism for adiponectin-dependent m2 macrophage 
polarization: link between the metabolic and innate immune 
activity of full-length adiponectin. J biol Chem. 2011;286:13460-9. 
medline:21357416 doi:10.1074/jbc.m110.204644
23 Park PH, Huang H, mcmullen mR, mandal P, sun l, nagy le. 
suppression of lipopolysaccharide-stimulated tumor necrosis 
factor-alpha production by adiponectin is mediated by 
transcriptional and post-transcriptional mechanisms. J biol Chem. 
2008;283:26850-8. medline:18678874 doi:10.1074/jbc.m802787200
24 nishiwaki s, terakura s, ito m, Goto t, seto A, Watanabe K, et al. 
impact of macrophage infiltration of skin lesions on survival after 
allogeneic stem cell transplantation: a clue to refractory graft-
versus-host disease. blood. 2009;114:3113-6. medline:19643987 
doi:10.1182/blood-2009-03-209635
25 Haniffa m, Ginhoux F, Wang Xn, bigley V, Abel m, dimmick i, et al. 
differential rates of replacement of human dermal dendritic cells 
and macrophages during hematopoietic stem cell transplantation. 
J exp med. 2009;206:371-85. medline:19171766 doi:10.1084/
jem.20081633
26 Okamoto Y, Folco eJ, minami m, Wara AK, Feinberg mW, sukhova 
GK, et al. Adiponectin inhibits the production of CXC receptor 3 
chemokine ligands in macrophages and reduces t-lymphocyte 
recruitment in atherogenesis. Circ Res. 2008;102:218-25. 
medline:17991878 doi:10.1161/CiRCResAHA.107.164988
27 Okamoto Y, Christen t, shimizu K, Asano K, Kihara s, mitchell 
GRAFT-VS-HOST DISEASE 264 Croat Med J. 2016;57:255-65
www.cmj.hr
Rn, et al. Adiponectin inhibits allograft rejection in murine 
cardiac transplantation. transplantation. 2009;88:879-83. 
medline:19935458 doi:10.1097/tP.0b013e3181b6efbf
28 stofkova A. Resistin and visfatin: regulators of insulin sensitivity, 
inflammation and immunity. endocr Regul. 2010;44:25-36. 
medline:20151765 doi:10.4149/endo_2010_01_25
29 Haluzik m, Haluzikova d. the role of resistin in obesity-induced 
insulin resistance. Curr Opin investig drugs. 2006;7:306-11. 
medline:16625816
30 Jamaluddin ms, Weakley sm, Yao Q, Chen C. Resistin: functional 
roles and therapeutic considerations for cardiovascular disease. 
br J Pharmacol. 2012;165:622-32. medline:21545576 doi:10.1111/
j.1476-5381.2011.01369.x
31 tanaka n, Kusunoki n, Kusunoki Y, Hasunuma t, Kawai s. Resistin 
is associated with the inflammation process in patients with 
systemic autoimmune diseases undergoing glucocorticoid 
therapy: comparison with leptin and adiponectin. mod Rheumatol. 
2013;23:8-18. medline:22434063 doi:10.3109/s10165-012-0623-z
32 Rae C, Graham A. Human resistin promotes macrophage lipid 
accumulation. diabetologia. 2006;49:1112-4. medline:16532325 
doi:10.1007/s00125-006-0187-6
33 Qatanani m, szwergold nR, Greaves dR, Ahima Rs, lazar mA. 
macrophage-derived human resistin exacerbates adipose 
tissue inflammation and insulin resistance in mice. J Clin invest. 
2009;119:531-9. medline:19188682 doi:10.1172/JCi37273
34 nakasone H, binh Pn, Yamazaki R, tanaka Y, sakamoto K, Ashizawa 
m, et al. Association between serum high-molecular-weight 
adiponectin level and the severity of chronic graft-versus-host 
disease in allogeneic stem cell transplantation recipients. blood. 
2011;117:3469-72. medline:21258011 doi:10.1182/blood-2010-10-
316109
35 Hirose H, Yamamoto Y, seino-Yoshihara Y, Kawabe H, saito i. 
serum high-molecular-weight adiponectin as a marker for 
the evaluation and care of subjects with metabolic syndrome 
and related disorders. J Atheroscler thromb. 2010;17:1201-11. 
medline:20948162 doi:10.5551/jat.6106
36 Arita Y, Kihara s, Ouchi n, takahashi m, maeda K, miyagawa J, et al. 
Paradoxical decrease of an adipose-specific protein, adiponectin, 
in obesity. biochem biophys Res Commun. 1999;257:79-83. 
medline:10092513 doi:10.1006/bbrc.1999.0255
37 Cnop m, Havel PJ, utzschneider Km, Carr db, sinha mK, boyko 
eJ, et al. Relationship of adiponectin to body fat distribution, 
insulin sensitivity and plasma lipoproteins: evidence for 
independent roles of age and sex. diabetologia. 2003;46:459-69. 
medline:12687327
38 staiger H, tschritter O, machann J, thamer C, Fritsche A, maerker e, 
et al. Relationship of serum adiponectin and leptin concentrations 
with body fat distribution in humans. Obes Res. 2003;11:368-72. 
medline:12634431 doi:10.1038/oby.2003.48
39 Przepiorka d, Weisdorf d, martin P, Klingemann HG, beatty P, Hows 
J, et al. 1994 Consensus Conference on Acute GVHd Grading. bone 
marrow transplant. 1995;15:825-8. medline:7581076
40 Glucksberg H, storb R, Fefer A, buckner Cd, neiman Pe, Clift 
RA, et al. Clinical manifestations of graft-versus-host disease 
in human recipients of marrow from Hl-A-matched sibling 
donors. transplantation. 1974;18:295-304. medline:4153799 
doi:10.1097/00007890-197410000-00001
41 tomblyn m, Chiller t, einsele H, Gress R, sepkowitz K, storek 
J, et al. Guidelines for preventing infectious complications 
among hematopoietic cell transplantation recipients: a global 
perspective. biol blood marrow transplant. 2009;15:1143-238. 
medline:19747629 doi:10.1016/j.bbmt.2009.06.019
42 Fantuzzi G. Adiponectin in inflammatory and immune-mediated 
diseases. Cytokine. 2013;64:1-10. medline:23850004 doi:10.1016/j.
cyto.2013.06.317
43 Yamauchi t, Kamon J, Waki H, terauchi Y, Kubota n, Hara K, 
et al. the fat-derived hormone adiponectin reverses insulin 
resistance associated with both lipoatrophy and obesity. nat med. 
2001;7:941-6. medline:11479627 doi:10.1038/90984
44 simpson ns, banks s, Arroyo s, dinges dF. effects of sleep 
restriction on adiponectin levels in healthy men and women. 
Physiol behav. 2010;101:693-8. medline:20723551 doi:10.1016/j.
physbeh.2010.08.006
45 silha JV, Krsek m, skrha JV, sucharda P, nyomba bl, murphy lJ. 
Plasma resistin, adiponectin and leptin levels in lean and obese 
subjects: correlations with insulin resistance. eur J endocrinol. 
2003;149:331-5. medline:14514348 doi:10.1530/eje.0.1490331
46 nikolousis e, nagra s, Paneesha s, delgado J, Holder K, bratby l, et 
al. Allogeneic transplant outcomes are not affected by body mass 
index (bmi) in patients with haematological malignancies. Ann 
Hematol. 2010;89:1141-5. medline:20544351 doi:10.1007/s00277-
010-1001-6
47 navarro WH, loberiza FR Jr, bajorunaite R, van besien K, Vose 
Jm, lazarus Hm, et al. effect of body mass index on mortality of 
patients with lymphoma undergoing autologous hematopoietic 
cell transplantation. biol blood marrow transplant. 2006;12:541-51. 
medline:16635789 doi:10.1016/j.bbmt.2005.12.033
48 lange bJ, Gerbing Rb, Feusner J, skolnik J, sacks n, smith FO, et 
al. mortality in overweight and underweight children with acute 
myeloid leukemia. JAmA. 2005;293:203-11. medline:15644547 
doi:10.1001/jama.293.2.203
49 Jaime-Perez JC, Colunga-Pedraza PR, Gutierrez-Gurrola b, brito-
Ramirez As, Gutierrez-Aguirre H, Cantu-Rodriguez OG, et al. 
Obesity is associated with higher overall survival in patients 
undergoing an outpatient reduced-intensity conditioning 
hematopoietic stem cell transplant. blood Cells mol dis. 
2013;51:61-5. medline:23422842 doi:10.1016/j.bcmd.2013.01.010
50 Annaloro C, usardi P, Airaghi l, Giunta V, Forti s, Orsatti A, et al. 
Prevalence of metabolic syndrome in long-term survivors of 
hematopoietic stem cell transplantation. bone marrow transplant. 
265Robak et al: Adiponectin and resistin in allogeneic HSCT
www.cmj.hr
2008;41:797-804. medline:18195686 doi:10.1038/sj.bmt.1705972
51 Katsiougiannis s, tenta R, skopouli Fn. Activation of AmP-activated 
protein kinase by adiponectin rescues salivary gland epithelial 
cells from spontaneous and interferon-gamma-induced apoptosis. 
Arthritis Rheum. 2010;62:414-9. medline:20112400
52 tomizawa A, Hattori Y, Kasai K, nakano Y. Adiponectin induces nF-
kappab activation that leads to suppression of cytokine-induced 
nF-kappab activation in vascular endothelial cells: globular 
adiponectin vs. high molecular weight adiponectin. diab Vasc dis 
Res. 2008;5:123-7. medline:18537100 doi:10.3132/dvdr.2008.020
53 Haugen F, drevon CA. Activation of nuclear factor-kappab by 
high molecular weight and globular adiponectin. endocrinology. 
2007;148:5478-86. medline:17702846 doi:10.1210/en.2007-0370
54 neumeier m, Weigert J, schaffler A, Wehrwein G, muller-ladner 
u, scholmerich J. Wet al. different effects of adiponectin 
isoforms in human monocytic cells. J leukoc biol. 2006;79:803-8. 
medline:16434692 doi:10.1189/jlb.0905521
55 turner JJ, smolinska mJ, sacre sm, Foxwell bm. induction of tlR 
tolerance in human macrophages by adiponectin: does lPs play 
a role? scand J immunol. 2009;69:329-36. medline:19284497 
doi:10.1111/j.1365-3083.2008.02224.x
56 Wedellova Z, Kovacova Z, tencerova m, Vedral t, Rossmeislova 
l, siklova-Vitkova m, et al. the impact of full-length, trimeric 
and globular adiponectin on lipolysis in subcutaneous and 
visceral adipocytes of obese and non-obese women. Plos 
One. 2013;8:e66783. medline:23805277 doi:10.1371/journal.
pone.0066783
57 Chedid P, Hurtado-nedelec m, marion-Gaber b, bournier O, 
Hayem G, Gougerot-Pocidalo mA, et al. Adiponectin and its 
globular fragment differentially modulate the oxidative burst 
of primary human phagocytes. Am J Pathol. 2012;180:682-92. 
medline:22119038 doi:10.1016/j.ajpath.2011.10.013
58 brochu-Gaudreau K, Rehfeldt C, blouin R, bordignon V, murphy 
bd, Palin mF. Adiponectin action from head to toe. endocrine. 
2010;37:11-32. medline:20963555 doi:10.1007/s12020-009-9278-8
